NEW YORK, Dec. 11 - AxCell Biosciences said Tuesday it had agreed to run a pilot program for Pluvita to determine protein interactions based on signal transduction research.
Axcell said it would identify full-length peptides that bind to a compound Pluvita has earmarked for the research program.
Financial and other terms of the agreement were not disclosed.
The deal signals a furthering of the relationship between the two companies. Last month, Pluvita of Bethesda, Md., signed a three-year deal for access to AxCell ProChart database, which contains information on signal transduction pathways in the human proteome.
"AxCell's platform technology should help us to identify drugs that target pathways related to a specific disease while avoiding the pathways associated with unwanted side effects,” Gary Kurtzman, CEO of Pluvita, said in a statement.
Pluvita is developing drugs for cancer and reproductive diseases.
AxCell Biosciences of Princeton, NJ, is a subsidiary of Cytogen.